Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Phase IV Website Planned For October 2001; Final Tracking Rule Issued

Executive Summary

FDA plans to launch a website on the status of pharmaceutical company Phase IV commitments by Oct. 1, 2001.

You may also be interested in...



PDUFA III Authorizes FDA To Alert MDs To Failed Phase IV Commitments

FDA will have the authority to require manufacturers to inform prescribers if they fail to complete Phase IV commitments under the Prescription Drug User Fee Act reauthorization

PDUFA III Authorizes FDA To Alert MDs To Failed Phase IV Commitments

FDA will have the authority to require manufacturers to inform prescribers if they fail to complete Phase IV commitments under the Prescription Drug User Fee Act reauthorization

Phase IV study commitments pending

FDA's Phase IV website will include a database of about 1,700 commitments when it launches, the agency said (1"The Pink Sheet" Oct. 30, 2000, p. 4). FDA will report to Congress that 2,200 of the 3,000 post-marketing commitments in its database are currently outstanding; about 500 involve chemistry studies and, because they are proprietary, will not be included on the public web page. The report was due Oct. 1...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel